Skip to content

MAZE MAZE Short- term Investments

Short- term Investments at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Septerna, Inc. logo
Septerna, Inc.SEPN
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
Schrodinger logo
SchrodingerSDGR
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's short- term investments?
MAZE (MAZE) reported short- term investments of $153.62M in Q1 2026.